Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in <scp>SM</scp> and <scp>AHNMD</scp> components

Sa A. Wang(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda, Yang O. Huh(The University of Texas MD Anderson Cancer Center), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Dan Jones(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Lloyd Hutchinson(University of Massachusetts Chan Medical School), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Patricia M. Miron(Memorial Medical Center), Su S. Chen(The University of Texas MD Anderson Cancer Center)
American Journal of Hematology
December 19, 2012
10.1002/ajh.23380
Cited by 87

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Inhibition of JNK activation through NF-κB target genes
|Nature|2001|719
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
|Blood|2006|468